Halozyme's ENHANZE technology drives strong near-term growth, but its key patent expires in 2027. Click here to find out why HALO is downgraded to Hold.

In the same vein as weather forecast models that predict developing storms, researchers now have developed a method to ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating ...

Merck & Co., Inc. (NYSE: MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention ...

Halozyme Therapeutics HALO has outperformed the market over the past 15 years by 2.0% on an annualized basis producing an average annual return of 14.27%. Currently, Halozyme Therapeutics has a ...

Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an approximately $10 billion deal.

Principal Financial Group Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the Securities ...

MRK's regulatory filing for once-daily HIV pill DOR/ISL gets FDA acceptance, with a decision expected by April 2026.

Verona Pharma surged by 20.62 percent on Wednesday to end at $104.77 per share following news that it was being acquired by US-based pharmaceutical company Merck for $10 billion.